935 related articles for article (PubMed ID: 18081598)
21. Breast cancer risk in postmenopausal women using estrogen-only therapy.
Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2006 Dec; 108(6):1354-60. PubMed ID: 17138766
[TBL] [Abstract][Full Text] [Related]
22. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
Ettinger B; Pressman A
Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
[TBL] [Abstract][Full Text] [Related]
23. [Hormone replacement therapy and cancer of the breast. 1. Does replacement therapy increase the risk of cancer of the breast?].
Ayres de Campos D; Barros H; Martinez de Oliveira J
Acta Med Port; 1997 Oct; 10(10):697-703. PubMed ID: 9477595
[TBL] [Abstract][Full Text] [Related]
24. Hormone replacement therapy and risk of breast cancer: the role of progestins.
Stahlberg C; Pedersen AT; Lynge E; Ottesen B
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
[TBL] [Abstract][Full Text] [Related]
25. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group.
Brinton LA; Hoover RN
Obstet Gynecol; 1993 Feb; 81(2):265-71. PubMed ID: 8380913
[TBL] [Abstract][Full Text] [Related]
26. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
[TBL] [Abstract][Full Text] [Related]
27. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
28. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
29. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
[TBL] [Abstract][Full Text] [Related]
30. Statins and breast cancer in postmenopausal women without hormone therapy.
Eaton M; Eklof J; Beal JR; Sahmoun AE
Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
[TBL] [Abstract][Full Text] [Related]
31. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
32. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for in situ breast cancer.
Longnecker MP; Bernstein L; Paganini-Hill A; Enger SM; Ross RK
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):961-5. PubMed ID: 8959317
[TBL] [Abstract][Full Text] [Related]
34. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women.
Lindblad BE; Håkansson N; Philipson B; Wolk A
Ophthalmology; 2010 Mar; 117(3):424-30. PubMed ID: 20045566
[TBL] [Abstract][Full Text] [Related]
36. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
37. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer.
Slattery ML; Potter JD; Curtin K; Edwards S; Ma KN; Anderson K; Schaffer D; Samowitz WS
Cancer Res; 2001 Jan; 61(1):126-30. PubMed ID: 11196149
[TBL] [Abstract][Full Text] [Related]
38. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
[TBL] [Abstract][Full Text] [Related]
39. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
Cerhan JR; Vachon CM; Habermann TM; Ansell SM; Witzig TE; Kurtin PJ; Janney CA; Zheng W; Potter JD; Sellers TA; Folsom AR
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1466-71. PubMed ID: 12433728
[TBL] [Abstract][Full Text] [Related]
40. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis.
Garbe E; Levesque L; Suissa S
Maturitas; 2004 Mar; 47(3):175-83. PubMed ID: 15036487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
